Scrip
US FDA approves AstraZeneca's Crestor for broader patient population
09 February 2010
Asher Mullard
Please Login to read the full article.
09 February 2010
Asher Mullard
The US FDA has expanded the approval of AstraZeneca's Crestor (rosuvastatin) such that it can now be used to prevent heart disease in individuals with normal low-density lipoprotein (LDL) levels and no clinically relevant heart disease, so long as they have other risk factors.
As...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Abbott's Niaspan beats Merck & Co's Zetia in halted trial
- Isis's mipomersen passes second Phase III trial, but safety concerns spook investors
- US FDA advisors back AstraZeneca's Crestor for CV disease prevention
- ACCORD LIPID: Fenofibrates fail to improve cardiovascular outcomes type 2 diabetics
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
